ALHC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALHC's Advanced Deterministic Scorecard reveals significant financial health concerns, with a Piotroski F-Score of 2/9 indicating weak operational and financial stability. The absence of an Altman Z-Score and the company's high debt/equity ratio of 1.84 raise distress risk concerns, especially given negative profitability metrics and a lack of positive cash flow indicators. Despite strong revenue growth (44.4% YoY) and impressive earnings surprises in recent quarters, the company remains unprofitable with negative ROE (-0.70%) and ROA (1.00%), undermining long-term sustainability. Insider selling totaling $454.78M over six months signals strong bearish sentiment from leadership, further eroding confidence. The stock trades at a premium valuation (Price/Book: 21.89) despite poor profitability, suggesting overvaluation relative to fundamentals.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALHC vs LLY: Head-to-Head Comparison
This page compares Alignment Healthcare, Inc. (ALHC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.